List of Excipients in Branded Drug LYSODREN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	LYSODREN	mitotane	0015-3080	CELLULOSE, MICROCRYSTALLINE
ER Squibb & Sons LLC	LYSODREN	mitotane	0015-3080	POLYETHYLENE GLYCOL 3350
ER Squibb & Sons LLC	LYSODREN	mitotane	0015-3080	SILICON DIOXIDE
ESTEVE PHARMACEUTICALS SA	LYSODREN	mitotane	68118-080	CELLULOSE, MICROCRYSTALLINE
ESTEVE PHARMACEUTICALS SA	LYSODREN	mitotane	68118-080	POLYETHYLENE GLYCOL 3350

Lysodren Excipient Strategy and Commercial Opportunities for Mitotane

Last updated: September 24, 2026

Lysodren is an oral 500 mg mitotane tablet used for adrenal cortical carcinoma. Its commercial opportunity is driven less by conventional volume growth than by specialty-generic entry, excipient optimization, supply reliability, and differentiated oral delivery. The product has an old active ingredient, a narrow patient population, high clinical monitoring requirements, and formulation characteristics that create both development barriers and niche opportunities.

What is Lysodren and how is mitotane formulated?

Lysodren contains mitotane, an adrenolytic active pharmaceutical ingredient used to treat inoperable, metastatic, or recurrent adrenal cortical carcinoma. The marketed product is a 500 mg immediate-release tablet administered orally with food to improve absorption and reduce gastrointestinal intolerance.[1]

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent and tablet compressibility aid
Corn starch	Binder, disintegrant, and filler
Hypromellose	Binder or film-forming agent
Polysorbate 80	Wetting or dispersion aid
Sodium lauryl sulfate	Surfactant and wetting agent
Talc	Glidant and anti-sticking agent

The formulation is conventional, but mitotane creates several technical constraints. The active ingredient is highly lipophilic, has variable oral absorption, and is associated with gastrointestinal adverse effects. Its pharmacokinetics are also variable across patients, which makes consistent dissolution, food interaction, and dose titration commercially important.[1,2]

What excipient functions matter most for mitotane?

The principal formulation objectives are:

1. Improve wetting and dissolution of a poorly water-soluble active.
2. Maintain tablet robustness at a high drug load.
3. Support rapid but reproducible disintegration.
4. Limit sensitivity to manufacturing scale-up.
5. Preserve stability during long-term storage.
6. Avoid new excipient-related gastrointestinal or hypersensitivity risks.

Polysorbate 80 and sodium lauryl sulfate appear to address the wetting and dispersion challenges associated with mitotane’s lipophilicity. Microcrystalline cellulose and corn starch support tablet manufacture and disintegration. Hypromellose can improve granulation and mechanical strength, while talc supports powder flow and tablet ejection.

The commercial implication is that excipient substitution may affect bioavailability. A generic developer cannot assume that a compositionally similar tablet will produce clinically equivalent exposure without adequate comparative dissolution and bioequivalence evidence.

What excipient strategy is most suitable for Lysodren?

A practical strategy is to preserve the established immediate-release profile while improving manufacturability and dissolution control. A full reformulation into a novel delivery system may create unnecessary regulatory and clinical risk unless it addresses a documented product limitation.

Strategy 1: Conservative generic-equivalent formulation

The lowest-risk approach is to use the same broad excipient architecture:

• Microcrystalline cellulose as the principal filler.
• Corn starch or a comparable disintegrant.
• A low-level surfactant system.
• Hypromellose as a binder.
• Talc or another accepted glidant.

This approach may support an Abbreviated New Drug Application if the applicant can demonstrate pharmaceutical equivalence and bioequivalence. The principal development challenge is reproducing the reference product’s dissolution and food-effect behavior rather than creating a novel dosage form.

Strategy 2: Improved wetting and dissolution

A developer could evaluate alternatives to polysorbate 80 and sodium lauryl sulfate, including:

• Sodium lauryl sulfate at a controlled concentration.
• Poloxamers.
• Docusate salts.
• Crospovidone or croscarmellose sodium combined with a wetting agent.
• Lipid-based excipient systems.
• Spray-dried or co-processed excipient platforms.

The goal would be a more reproducible dissolution profile with lower surfactant loading. Excessive surfactant can increase gastrointestinal irritation, alter tablet mechanical properties, or create stability concerns.

Strategy 3: Lipid-enabled oral delivery

Because mitotane is lipophilic, a lipid-based formulation could improve dispersion in gastrointestinal fluids. Candidate technologies include self-emulsifying drug delivery systems, solid lipid dispersions, and amorphous solid dispersions.

This strategy has commercial value if it can reduce food dependence or improve exposure consistency. It also carries higher risk. A formulation that increases systemic exposure may alter tolerability, steroid replacement requirements, or the therapeutic window. The product label emphasizes therapeutic drug monitoring and gradual titration, so an exposure-enhancing formulation would require careful clinical justification.[1]

Strategy 4: Taste, swallowability, and dose-flexibility improvements

Lysodren tablets are large-dose solid oral units. Opportunities include:

• Lower-dose tablets for titration.
• Scored tablets, if mechanical testing supports accurate subdivision.
• Film coating to reduce handling and improve swallowability.
• Multiple-strength packaging.
• Blister packaging for specialty distribution.
• An oral suspension or granule formulation for patients with swallowing difficulty.

A liquid or multiparticulate product could support dose titration, but it would create additional stability, preservative, microbial, dosing-accuracy, and regulatory requirements.

What commercial opportunities exist for Lysodren excipients?

The strongest opportunities are in generic substitution, formulation services, contract manufacturing, and specialty packaging.

Opportunity	Commercial rationale	Development risk
Authorized or standard generic tablet	Established dosage form and high unit value	Small market and bioequivalence complexity
Lower-cost excipient replacement	Potential margin improvement and supply resilience	Dissolution and stability changes
Improved wetting formulation	May reduce exposure variability	Requires comparative performance data
Multiple-strength product line	Supports titration and patient convenience	Manufacturing and regulatory expansion
Oral liquid or granule	Addresses swallowing and flexible dosing	Higher CMC and stability burden
Specialty blister packaging	Supports adherence and handling	Limited effect on clinical differentiation
Contract development and manufacturing	Specialized niche with limited competitors	Small addressable market
Regional supply partnership	Can address shortages and access gaps	Regulatory and distribution complexity

The market is structurally attractive for high-margin specialty suppliers because the patient population is small and treatment is concentrated in oncology and endocrinology centers. The same factors constrain overall sales volume. A formulation supplier should therefore target a portfolio strategy involving mitotane alongside other orphan oncology products rather than rely on Lysodren alone.

How large is the market opportunity for Lysodren?

Lysodren addresses a rare cancer indication. Adrenal cortical carcinoma has a low incidence, and only a subset of patients receive mitotane. Treatment can be prolonged, but use is limited by disease prevalence, tolerability, monitoring, and specialist prescribing.

The commercial model is therefore based on value per treated patient rather than broad prescription volume. Relevant revenue drivers include:

• Annual treatment duration.
• Dose escalation and maintenance requirements.
• Geographic access to mitotane.
• Generic price erosion.
• Availability of competing mitotane sources.
• Use in adjuvant versus advanced disease.
• Clinical preference for the established product.

The product label recommends initiating treatment at a low dose and increasing it gradually, with plasma mitotane monitoring used to guide treatment.[1] This creates demand for dosage flexibility and reliable tablet content uniformity. It also makes a formulation that materially changes exposure commercially risky, even if it improves dissolution in vitro.

What patents protect Lysodren and mitotane formulations?

Mitotane has been used clinically for decades, and the original active-ingredient and basic product patents are not expected to provide meaningful current exclusivity. The commercial protection for a new entrant is more likely to arise from regulatory status, manufacturing know-how, formulation patents, trademarks, and supply reliability than from the original compound patent.

Potentially protectable subject matter includes:

• A specific particle-size distribution.
• A defined polymorphic or crystalline form.
• A solid dispersion with a named polymer.
• A surfactant concentration range.
• A controlled-dissolution tablet.
• A food-independent formulation.
• A multiparticulate or liquid dosage form.
• A manufacturing process that improves content uniformity.
• Packaging that improves stability or reduces handling exposure.

A formulation patent would need to claim a meaningful technical advantage. Broad claims covering ordinary tablet excipients would face validity and obviousness risks, particularly for a decades-old active ingredient.

What is the Orange Book status of Lysodren?

Lysodren is an old small-molecule product rather than a recently launched protected medicine. The principal regulatory route for a conventional generic would generally be an ANDA if an appropriate reference listed drug and product information are available. A materially different dosage form could require a 505(b)(2) application.

A current Orange Book review should distinguish among:

• The reference listed drug.
• Any active patent listing.
• Any remaining pediatric or other regulatory exclusivity.
• Whether a generic applicant can file with Paragraph IV certification.
• Whether a listed patent is relevant to the proposed formulation.

For an old mitotane tablet, the main commercial risk is usually not compound-patent litigation. It is the cost of development relative to the small market and the difficulty of demonstrating equivalent performance.

When does Lysodren lose exclusivity and when can generics launch?

The original exclusivity period for mitotane has long elapsed. Generic entry is therefore legally possible in principle, subject to FDA requirements, reference-product availability, application approval, and any currently enforceable listed patents.

A generic launch could follow several scenarios:

Launch scenario	Product profile	Main barrier
Standard ANDA	Immediate-release 500 mg tablet	Bioequivalence and commercial scale
ANDA with alternative excipients	Same dosage form and strength	Dissolution and food-effect matching
505(b)(2) formulation	New liquid, granule, or modified tablet	Clinical and CMC evidence
Authorized generic	Reference-like product	Access to product and manufacturing rights
Regional generic	Country-specific approval	Limited market size and distribution
Compounded alternative	Patient-specific preparation	Quality, stability, and consistency limits

Paragraph IV challenges are possible if an active Orange Book patent covers the reference product or a relevant method of use. For an old mitotane tablet, a successful Paragraph IV strategy would more likely target a later formulation patent than the original mitotane invention.

What regulatory issues affect an excipient-based Lysodren product?

FDA review would focus on pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, and product quality. Key development elements include:

• Assay and content uniformity.
• Tablet hardness and friability.
• Disintegration and dissolution across pH conditions.
• Impurity and degradation-product control.
• Stability under long-term and accelerated conditions.
• Surfactant compatibility.
• Food-effect assessment where relevant.
• Manufacturing-process validation.
• Container-closure performance.

The product is also a hazardous drug from a manufacturing and handling perspective. Mitotane’s cytotoxic and endocrine effects require controlled occupational exposure procedures, containment, cleaning validation, and specialized waste management.[1,3]

Excipient changes should be evaluated for effects on:

• Mitotane absorption.
• Gastrointestinal tolerability.
• Plasma concentration variability.
• Dose titration.
• Stability in high-humidity conditions.
• Patient handling and tablet splitting.

What manufacturing and intellectual-property barriers exist?

The manufacturing barriers are more significant than the active ingredient’s basic patent position.

Manufacturing barriers

Mitotane development may require:

• Contained weighing and dispensing.
• Dedicated or segregated production areas.
• Validated cleaning procedures.
• Specialized worker-protection systems.
• Low-volume, high-value batch economics.
• Reliable sourcing of pharmaceutical-grade mitotane.
• Stability data for a lipophilic active and surfactant-containing formulation.

Small production runs can raise unit costs. A supplier with existing oncology containment infrastructure has an advantage over a general-purpose tablet manufacturer.

Intellectual-property barriers

Potential barriers include:

• Patents on a later formulation.
• Trade secrets covering particle engineering.
• Proprietary manufacturing processes.
• Regulatory exclusivity for a newly approved dosage form.
• Trademark and packaging rights.
• Confidential supply agreements.
• Distribution arrangements with specialty oncology providers.

The practical defense for a new product is often a combination of formulation know-how, reliable supply, regulatory execution, and specialist distribution.

Which companies are challenging Lysodren?

The competitive field is likely to consist of the established Lysodren product, potential generic manufacturers, regional suppliers, and compounding pharmacies. A definitive current list of active ANDA applicants, litigation defendants, or Paragraph IV challengers is not established in the publicly cited product materials.

Mitotane has a different competitive profile from large-market oncology drugs. Competition is less likely to arise from numerous simultaneous generic launches. Instead, market entry may occur through one or two specialty suppliers that accept a limited-volume product with high technical and regulatory requirements.

How does Lysodren compare with other adrenal cortical carcinoma therapies?

Mitotane is differentiated by its direct adrenolytic activity and established role in adrenal cortical carcinoma. It is also used with glucocorticoid and mineralocorticoid replacement when adrenal insufficiency develops.[1]

Product category	Role relative to mitotane	Excipient opportunity
Mitotane tablet	Disease-specific adrenolytic therapy	Dissolution, dose flexibility, supply
Cytotoxic chemotherapy	Used in selected advanced disease	Conventional oral or injectable platforms
Steroid replacement	Manages treatment-related adrenal insufficiency	Adherence and combination packaging
Immunotherapy	Investigational or selected later-line use	Less direct relevance to mitotane excipients
Compounded mitotane	May address access or dose needs	Quality and consistency concerns

The most credible commercial positioning is not a broad oncology replacement strategy. It is a dependable, lower-cost, or more patient-friendly mitotane product supported by specialist distribution.

What licensing deals could support a Lysodren opportunity?

A commercial entrant could pursue:

• An exclusive regional license for an approved mitotane product.
• A contract manufacturing agreement with an oncology containment facility.
• A formulation-development partnership with an excipient or drug-delivery company.
• A specialty-pharmacy distribution agreement.
• A co-development deal for lower-dose or liquid mitotane.
• A supply agreement for pharmaceutical-grade mitotane API.

Licensing economics must reflect the small patient population. Upfront payments and minimum purchase commitments should be limited unless the partner brings an approved product, protected formulation, or established access to oncology centers.

Key Takeaways

• Lysodren is a 500 mg immediate-release mitotane tablet for adrenal cortical carcinoma.
• Its listed excipients are microcrystalline cellulose, corn starch, hypromellose, polysorbate 80, sodium lauryl sulfate, and talc.[1]
• The main technical issue is reproducible absorption of a highly lipophilic active, not basic tablet compression.
• Conservative excipient substitution is lower risk than a major delivery-system redesign.
• Lipid-based, amorphous, liquid, and multiparticulate formulations offer differentiation but increase regulatory and clinical risk.
• Original mitotane exclusivity has long expired; current entry risk depends on any later-listed formulation patents, regulatory requirements, and commercial economics.
• The best commercial opportunities are specialty generic supply, dose-flexible products, manufacturing partnerships, and improved formulation technologies.
• Manufacturing containment and low-volume economics are meaningful barriers.
• A successful product must preserve predictable exposure and support therapeutic drug monitoring.

FAQs About Lysodren Excipient and Commercial Strategy

Can Lysodren be reformulated as a capsule?

Yes, but a capsule would require comparative dissolution, stability, and bioequivalence assessment. The capsule shell, fill formulation, and surfactant system could change drug release and exposure.

Would a liquid mitotane product have commercial value?

Potentially. A liquid could support dose titration and swallowing convenience, but it would require controls for sedimentation, dose uniformity, chemical stability, microbial quality, and handling exposure.

Is polysorbate 80 essential to Lysodren?

It is not necessarily irreplaceable, but it likely contributes to wetting or dispersion of the lipophilic active. Any replacement would require comparative performance testing.

Could an excipient change support a 505(b)(2) application?

Yes, if the proposed product differs materially from the reference product and relies partly on FDA findings for the established mitotane product. The regulatory pathway would depend on the dosage form, proposed labeling, and extent of formulation change.

Is a Lysodren shortage a formulation opportunity?

Yes. A supplier that can secure mitotane API, operate within appropriate containment controls, and maintain specialty distribution could create value through supply continuity even without a novel formulation.

References

1. U.S. Food and Drug Administration. (2023). Lysodren (mitotane) tablets: Prescribing information. Recordati Rare Diseases Inc.

2. Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Berruti, A., Sperone, P., Grossrubatscher, E., Reimondo, G., Bollito, E., Borretta, G., Papotti, M., Stigliano, A., Piccardo, A., Perotti, P., Montemurro, T., Zaggia, B., ... Arvat, E. (2007). Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine, 356(23), 2372-2380.

3. National Institute for Occupational Safety and Health. (2016). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. U.S. Centers for Disease Control and Prevention.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.